APA (7th ed.) Citation

HJ, C., SK, A., Y, O., LJ, N., L, F., SS, N., . . . JR, W. (2023). A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood advances, 7(7), 1137. https://doi.org/10.1182/bloodadvances.2022008174

Chicago Style (17th ed.) Citation

HJ, Cherng, et al. "A Phase 1/2 Study of Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed DLBCL." Blood Advances 7, no. 7 (2023): 1137. https://doi.org/10.1182/bloodadvances.2022008174.

MLA (9th ed.) Citation

HJ, Cherng, et al. "A Phase 1/2 Study of Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed DLBCL." Blood Advances, vol. 7, no. 7, 2023, p. 1137, https://doi.org/10.1182/bloodadvances.2022008174.